MEMPHIS, Tenn., Oct. 23, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children's Research Hospital scientists. The study will appear in the November 6 edition of the scientific journal Cell Reports.
The Board of Directors of Vigmed Holding AB (publ) has made a resolution to
publish the interim report for January - September 2014 earlier than previously
announced. The report will be published Friday 24 October 2014.
For further information contact:
Chairman of the board, Lennart Holm 46 70 630 8562 or CEO, Finn Ketler 46 42 600
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Styrelsen för Vigmed Holding AB (publ) har beslutat att tidigarelägga
publicering av delårsrapporten för januari – september 2014. Bolaget publicerar
rapporten fredagen den 24 oktober 2014.
För ytterligare information kontakta:
Styrelseordförande Lennart Holm 070 630 8562 eller VD Finn Ketler 042 600 5311
Vigmed är ett svenskt medicinteknikbolag med affärsidén att erbjuda marknaden
unika nålskyddade stickprodukter. Vigmed har sitt huvudkontor i Helsingborg och
sysselsätter ett 20-tal anställda.
-- Genmab to receive USD 10 million milestone payment from Janssen
-- Milestone triggered by progress in the Phase III study of daratumumab in
combination with bortezomib and dexamethasone
Copenhagen, Denmark; October 23, 2014 – Genmab A/S (OMX: GEN) announced today
it has reached the fourth milestone in its daratumumab collaboration with
Janssen Biotech, Inc. (“Janssen”). The USD 10 million milestone payment was
triggered by progress in the ongoing Phase II
DGAP-News: RHÃN-KLINIKUM AG / Key word(s): Share Buyback
RHÃN-KLINIKUM AG: Voluntary Notification Regarding the State of the
Acceptance of the Public
23.10.2014 / 18:32
NON-BINDING ENGLISH TRANSLATION
Voluntary Notification Regarding the State of the Acceptance of the Public
("Interim Result Notification")
On 15 October 2014, RHÃN-KLINIKUM Aktiengesellschaft (the "Company")
published the offer document
SAN RAFAEL, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Westamerica Bancorporation (Nasdaq:WABC) today declared a quarterly cash dividend of $0.38 per share on common stock outstanding to shareholders of record at the close of business November 3, 2014
NASDAQ OMX Derivatives Markets introduces new strikes from 2014-10-24.
For further information concerning this exchange notice please contact Product
Management, +46 8 405 69 70, or firstname.lastname@example.org.
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.